Online citations, reference lists, and bibliographies.
← Back to Search

Mésothéliome Pleural Malin

J. Bréchot
Published 2011 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Le mesotheliome pleural malin (MM) est une neoplasie primitive de la plevre. C’est une tumeur rare (906 cas en France en 2005). Son incidence a augmente entre 1980 et 1995 dans les deux sexes mais diminue actuellement chez l’homme et augmente de facon plus moderee chez la femme. Le role de l’amiante comme principal agent etiologique dans la survenue de cette neoplasie est acquis ; on retrouve une exposition a l’amiante dans 85 % des mesotheliomes pleuraux chez l’homme et dans 40 % chez la femme. La majorite de ces expositions est professionnelle.
This paper references
10.1002/(SICI)1097-4644(20000201)76:2<181::AID-JCB2>3.0.CO;2-9
Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations
N. Shivapurkar (1999)
10.1016/J.JTCVS.2004.10.034
Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: Staging implications.
J. Erasmus (2005)
10.1200/JCO.2011.41.5869
Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
H. Kindler (2012)
10.1097/RLI.0b013e3181817b3d
Computed Tomography, Positron Emission Tomography, Positron Emission Tomography/Computed Tomography, and Magnetic Resonance Imaging for Staging of Limited Pleural Mesothelioma: Initial Results
C. Plathow (2008)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1378/CHEST.108.4.1122
A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group.
V. Rusch (1995)
10.1016/s0761-8425(06)71591-1
Chimiothérapie du mésothéliome pleural malin: Recommandations de la Société de Pneumologie de Langue Française sur le mésothéliome pleural
T. Berghmans (2006)
10.1002/cncr.22552
Update on the molecular biology of malignant mesothelioma
A. Lee (2007)
10.1016/S0022-5223(19)36577-8
The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial.
V. Rusch (1991)
10.1097/00000658-199609000-00005
Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients.
D. Sugarbaker (1996)
10.1016/J.LUNGCAN.2005.10.016
EGFR overexpression in malignant pleural mesothelioma. An immunohistochemical and molecular study with clinico-pathological correlations.
A. Destro (2006)
10.1016/J.LUNGCAN.2006.08.012
EGFR expression: associations with outcome and clinicopathological variables in malignant pleural mesothelioma.
J. Edwards (2006)
10.1200/JCO.2006.06.8999
Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose
G. Ceresoli (2006)
10.1002/(SICI)1097-0142(19970901)80:5<948::AID-CNCR17>3.0.CO;2-W
Incidence of malignant pleural mesothelioma after thoracic radiotherapy
A. Neugut (1997)
10.1007/978-1-84628-012-2
Pathology of Malignant Mesothelioma
F. Galateau-Sallé (2006)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1200/JCO.2008.17.5604
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
M. D. de Perrot (2009)
10.1200/JCO.2005.04.3190
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
G. Ceresoli (2006)
10.1093/JNCI/DJI278
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
L. Travis (2005)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1016/J.LUNGCAN.2007.03.016
Malignant mesothelioma following thoracic radiotherapy for lung cancer.
S. Witherby (2007)
10.1378/CHEST.116.2.504
Advances in the treatment of malignant pleural mesothelioma.
D. Sterman (1999)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
10.1136/oem.2005.023200
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
[A plea for standardized thoracoscopy in malignant pleural mesothelioma].
M. Bard (2001)
10.1016/S0140-6736(00)04013-7
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Iman Roushdy-Hammady (2001)
10.1111/j.1365-2559.2005.02331.x
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data
J. King (2006)
10.1016/S0761-8425(06)71779-X
La conférence d'experts de la Société de Pneumologie de Langue Française (SPLF) sur le mésothéliome pleural malin (MPM) : des recommandations utiles et nécessaires
A. Scherpereel (2006)
10.3747/CO.2007.132
Phase II testing of sunitinib: the National Cancer Institute of Canada Clinical Trials Group IND Program Trials IND.182–185
R. Buckstein (2007)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1200/JCO.2007.12.5641
Phase II study of vinflunine in malignant pleural mesothelioma.
D. Talbot (2007)
10.1136/thx.2007.085241
EGFR and PDGFR differentially promote growth in malignant epithelioid mesothelioma of short and long term survivors
H. Kothmaier (2007)
10.1093/ANNONC/MDJ073
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
10.1016/J.EJCA.2006.07.011
Biology and management of malignant pleural mesothelioma.
P. Zucali (2006)
10.1002/cncr.23617
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
10.1016/j.radonc.2009.03.011
Pulmonary toxicity following IMRT after extrapleural pneumonectomy for malignant pleural mesothelioma.
C. Kristensen (2009)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.4267/10608/1279
Effets cellulaires et moléculaires de l'amiante
Marie-Claude Jaurand (1999)
10.1200/JCO.2008.19.8523
Malignant pleural mesothelioma.
A. Tsao (2009)
10.1200/JCO.2007.25.18_SUPPL.7707
Sorafenib in malignant mesothelioma (MM): A phase II trial of the Cancer and Leukemia Group B (CALGB 30307)
P. Jänne (2007)
Les effets sur la santé des principaux types d'exposition à l'amiante. Résultats d'une expertise collective de l'I.N.S.E.R.M. : Surveillance médicale des salariés exposés à l'amiante
M. Goldberg (1997)
10.1164/RCCM.200511-1789OC
Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma.
A. Scherpereel (2006)
10.1016/S0761-8425(06)71786-7
4.2. Chimiothérapie du mésothéliome pleural malin
T. Berghmans (2006)



Semantic Scholar Logo Some data provided by SemanticScholar